Biomerica vs Dyadic International
BMRA and DYAI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMRA and DYAI compare
Dyadic International is the larger company, worth 1.9 times as much as Biomerica ($11.7M against $6.1M).
Dyadic International grew revenue faster over the last twelve months (−7.6% versus −11.2% for Biomerica).
Biomerica keeps more of each dollar of sales as profit, with a net margin of −115% compared with −227% at Dyadic International.
Biomerica scores higher on the StockData Score (8 against 7 for Dyadic International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMRA | DYAI |
|---|---|---|
| Size and price | ||
| Market cap | $6.1M | $11.7M |
| Share price | $1.32 | $0.320 |
| Change, 1 year | −47.2% | −64.6% |
| Change, 5 years | −96.7% | −91.4% |
| Beta (5Y) | 0.84 | 1.44 |
| Employees | 17 | 5 |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 3 (better) | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.4× (better) | 3.8× |
| P/B | 1.7× | – |
| Fair value | $2.49 | – |
| Margin of safety | 47.0% | – |
| Growth | ||
| Revenue growth (TTM) | −11.2% | −7.6% (better) |
| Revenue growth, 5Y average | −9.2% | 14.0% (better) |
| Profitability | ||
| Gross margin | 0.90% | 17.9% (better) |
| Operating margin | −125% (better) | −237% |
| Net margin | −115% (better) | −227% |
| Return on equity | −114% (better) | −47256% |
| Return on invested capital | −284% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 1.91 (better) | 1.69 |
| Altman Z-score | −10.57 (better) | −18.95 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −52.2% | – |
| Shareholder yield | −52.2% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 2.7% | 12.7% |
| Held by insiders | 27.4% | 28.0% |
| Insider net buying, 12 months | $158K (better) | −$125K |
| Short interest, % of float | 0.37% | 0.32% |
Go deeper
- BMRA stock overview
- BMRA income statement
- BMRA valuation and score
- DYAI stock overview
- DYAI income statement
- DYAI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.